Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

ICARO

Financiado

Colloidal Inorganic Nanostructures for Radiotherapy and Chemotherapy

Radio and chemotherapy are the major clinical treatments for cancer. However these treatments lack cell specificity and can have severe side effects against healthy cells, especially when used in combination. My goal is to develop... ver más

31/12/2020

IIT

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-12-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-StG-2015: ERC Starting Grant

I+D

Cerrada hace 9 años

0% 100% 100%

3 Participantes

IIT

1.16M€ | Lider

PRODUCTOS ADITIVOS

217.98K€ | Participante

INT

112.50K€ | Participante

Proyectos interesantes

IJC2020-043198-I Electronic interactions on the nanoscale and their role in m... 98K€ Cerrado

MAT2009-14734-C02-02 DISEÑO DE NANOPARTICULAS INORGANICAS CONJUGADAS:NUEVAS HERRA... 61K€ Cerrado

MAT2009-14734-C02-01 DISEÑO DE NANOPARTICULAS INORGANICAS CONJUGADAS:NUEVAS HERRA... 97K€ Cerrado

TEC2009-14272 TECNOLOGIA PARA LA SINTESIS DE NANOCONJUGADOS PARA TERANOSTI... 109K€ Cerrado

PID2021-127033OB-C22 ESTUDIO FISICO-QUIMICO DEL EFECTO RADIOSENSIBILIZADOR DE NAN... 74K€ Cerrado

PID2021-124354NB-I00 NANOTERMOMETRO INTRACELULAR PARA EL ESTUDIO TERMICO DE LA FI... 85K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 58 meses Fecha Inicio: 2016-02-22
Fecha Fin: 2020-12-31

Líder del proyecto

FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA

TRL 4-5

Presupuesto del proyecto 1M€

Descripción del proyecto Radio and chemotherapy are the major clinical treatments for cancer. However these treatments lack cell specificity and can have severe side effects against healthy cells, especially when used in combination. My goal is to develop a nanocrystal (NC) platform to merge radio and chemotherapy into a single entity that is more specific towards tumor cells. To achieve ICARO’s goal, three main objectives will be pursued. The first objective is to introduce post-synthesis reactions, namely cation exchange (CE) and intercalation (INT) reactions, as new protocols to replace or intercalate cations that are useful as radionuclides within the crystal lattice of water-soluble NCs. Our goal is to establish protocols for the preparation of radiolabelled-NCs that will be easily translated to the medical practice for radiotherapy. This requires CE/INT reactions that occur in aqueous media, possibly with NCs prefunctionalized with specific recognition molecules to achieve targeted radiotherapy. To minimize the radio exposure of the operator, CE/INT protocols will be carried out as the last step of NC preparation. The second objective of ICARO will be to explore in situ CE/INT reactions with NCs entrapped in a matrix that simulates the tumor mass. By first located NCs at the tumor and then let the CE/INT to occur, enhance therapeutic effect is expected. The third objective of ICARO will be to develop heterostructures to combine radio and chemotherapy. They will include at least one semiconductor NC on which to perform radiolabelling protocols and one portion made of a superparamagnetic (SP) NC for magnetically triggered drug release. With respect to magnetic hyperthermia, which exploits SP-NCs to produce bulk heat (>46°C) at the tumor, the local heat effect generated at the surface of SP-NCs will enable drug release using a lower dose of magnetic material. Finally, new types of heterostructures combining radio and chemotherapy will be tested, for the first time, in preclinical trials.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores